Texanis
(Tranexamic Acid 500 mg/5 ml Injection)
Overview:
TEXANIS Injection contains Tranexamic Acid that acts by reversibly blocking lysine binding sites on plasminogen, thus preventing fibrin degradation and breaking down of of blood clots. Tranexamic acid may be considered as a first-line treatment for the initial management of idiopathic menorrhagia, especially for patients in whom hormonal treatment is either not recommended or not wanted.
Tranexamic acid belongs to the class of organic compounds known as carboxylic acids
TEXANIS Injections can be used in the treatment of following conditions:
For the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.
Short-term control of bleeding in hemophiliacs, including dental extraction procedures.
Conditions in which bleeding control is required such as after surgery or injury, recurrent nosebleeds or abnormal vaginal bleeding and menorrhagia.
For the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.
Short-term control of bleeding in hemophiliacs, including dental extraction procedures.
Conditions in which bleeding control is required such as after surgery or injury, recurrent nosebleeds or abnormal vaginal bleeding and menorrhagia.
5-10ml of TEXANIS Injection is given by slow intravenous injection at a rate of 1ml/minute, two to three times daily, or as directed by Physician.
Tranexamic acid competitively inhibits activation of plasminogen, thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.
Related Products
